Aim. To evaluate the performance of three contrast media (CM) injection protocols for cardiac computed tomography angiography (CCTA) based on body weight (BW), lean BW (LBW), and cardiac output (CO). Materials and methods. A total of 327 consecutive patients referred for CCTA were randomized into one of the three CM injection protocols, where CM injection was based on either BW (112 patients), LBW (108 patients), or CO (107 patients). LBW and CO were calculated via formulas. All scans were ECG-gated and performed on a third-generation dual-source CT with 70-120 kV (automated tube voltage selection) and 100 kV qual.ref /330 mAs qual.ref . CM injection protocols were also adapted to scan time and tube voltage. e primary outcome was the proportion of patients with optimal intravascular attenuation (325-500 HU). Secondary outcomes were mean and standard deviation of intravascular attenuation values (HU), contrast-to-noise ratio (CNR), and subjective image quality with a 4-point Likert scale (1 poor/2 su cient/3 good/4 excellent). e t-test for independent samples was used for pairwise comparisons between groups, and a chi-square test (χ2) was used to compare categorical variables between groups. All p values were 2-sided, and a p < 0.05 was considered statistically signi cant. Results. Mean overall HU and CNR were 423 ± 60HU/14 ± 3 (BW), 404 ± 62HU/14 ± 3 (LBW), and 413 ± 63HU/14 ± 3 (CO) with a signi cant di erence between groups BW and LBW (p 0.024). e proportion of patients with optimal intravascular attenuation (325-500 HU) was 83.9%, 84.3%, and 86.9% for groups BW, LBW, and CO, respectively, and between-group di erences were small and nonsigni cant. Mean CNR was diagnostic (≥10) in all groups. e proportion of scans with good-excellent image quality was 94.6%, 86.1%, and 90.7% in the BW, LBW, and CO groups, respectively. e di erence between proportions was signi cant between the BW and LBW groups. Conclusion. Personalization of CM injection protocols based on BW, LBW, and CO, and scan time and tube voltage in CCTA resulted in low variation between patients in terms of intravascular attenuation and a high proportion of scans with an optimal intravascular attenuation. e results suggest that personalized CM injection protocols based on LBW or CO have no additional bene t when compared with CM injection protocols based on BW.
Introduction
Cardiac computed tomography angiography (CCTA) is a valuable tool in ruling out coronary artery disease because of its high negative predictive value (99%) [1] [2] [3] [4] . Electrocardiogram gated CCTA imaging helps to minimize cardiac motion artifacts [5, 6] . Diagnostic accuracy for coronary artery assessment is achieved with a diagnostic intravascular attenuation (measured in Houns eld units (HU)) and contrast-to-noise ratio (CNR). Intravascular attenuation depends on scanner settings (e.g., tube voltage or tube potential), and characteristics of the administered contrast media injection protocol (CM) (e.g., concentration, iodine delivery rate (IDR)), and patient-related factors (e.g., cardiac output (CO) and body weight (BW)) [7] [8] [9] . IDR, which refers to the grams of iodine injected per second, is the most important factor for achieving diagnostic intravascular attenuation in CCTA [10] [11] [12] . Intravascular attenuation should be high enough to assess the coronary arteries (≥325HU) [7] . However, an intravascular attenuation >500 HU could lead to an underestimation of coronary calcifications [13] . erefore, intravascular attenuation in CCTA should ideally lie within an intravascular attenuation "window" of 325-500HU.
Nowadays, individualization of CM injection protocols based on certain patient parameters is a highly discussed topic. Many different techniques, varying from simple to complicated formulas with differing patient parameters have been suggested, e.g., BW, lean body weight (LBW), and CO [14] . Multiple studies show that individualization based on patients' BW or BW categories results in a diagnostic image quality throughout the patient population, together with decreased CM volumes [15] [16] [17] [18] .
LBW is a well-known measurement for body composition and is defined as the difference between BW and fatty tissue. Muscle tissue has an increased vascularization compared with fatty tissue [14] . In obese patients, blood volume does not increase linearly to BW. When adapting the CM injection protocol, the possibility of overestimating CM volumes could occur. LBW might be able to adjust for this.
Both blood volume and CO increase according to BW [14] . A higher CO increases the velocity of CM distribution [14] , resulting in faster CM bolus arrival and consequently a decreased and shortened intravascular peak attenuation profile compared to a lower CO. Timing and CM volume could be adjusted to CO in order to achieve a similar intravascular attenuation profile between patients with a different CO.
is study addresses the question of whether there are differences in performance between personalized CM injection protocols based on BW, LBW, or CO. e hypothesis is that personalization on either one of these three parameters does not result in a significantly different image quality. erefore, the aim of this study is to evaluate the performance of three individualized protocols based on BW, LBW, and CO for CCTA.
Materials and Methods

Ethics and Study Design.
e local ethical committee and institutional review board approved the study design (METC number: 16-1-110). is single center randomized controlled trial is registered on Clinicaltrials.gov under reference number NCT03292354.
All patients referred for a standard CCTA were eligible for inclusion. Patients were included after obtaining informed consent. Exclusion criteria were hemodynamic instability, pregnancy, renal insufficiency (GFR <30 mL/min/ 1.73 m 2 ), iodine allergy, age <18 years, and/or no informed consent. All clinically available scan protocols and tube voltages (70-120 kV) were included to simulate daily clinical practice. All patients were weighed just before scanning. After obtaining written informed consent, patients were randomized into one of three study groups: BW, LBW, or CO. Patient characteristics (i.e., age, height, BW, body mass index (BMI), LBW, and CO) and scan indication were recorded. Figure 1 shows the flowchart of the study design. [19] . is needle has three additional tear-drop shaped diffusion exit points close to the tip and a strengthened design that enables use with power injectors set up to 325 psi. e CM concentration was 300 mgI/mL (Iopromide, Bayer), prewarmed to body temperature (37°C; 98.6°F) and injected with help of a dual-head CT power injector (Stellant, Bayer).
Patients were randomized and enrolled in one of three CM injection protocols (Group 1: group BW; Group 2: group LBW; Group 3: group CO) with tailored flow rates and consequtively tailored IDRs. e injection protocols were defined with help of a formula, which has been explained extensively elsewhere [20] and can be found in Appendix 1. Besides personalization to these patient characteristics, the injection protocol was adapted to the tube voltage, as described in previous studies [21] [22] [23] [24] [25] . e following formulas were used: With BW in kg and L � length in cm (iii) CO: flow rate � 0.008916 * kV * CO (b) CO according to an adapted Katori formula [27] CO � (4.874 − 0.023 * age) * BSA With age in years and BSA � body surface area e formulas shown above determined the flow rates for both test bolus and main bolus. e injection time was fixed for the test bolus (2 s) and the three scan protocols: 8 s for flash and 10 s for adaptive sequence (AS) and helical. e CM volume of the test bolus and main bolus (mL) was then derived by multiplying the calculated flow rate (mL/s) with the injection time (s).
All relevant CM injection parameters were recorded by CM monitoring software (Certegra ™ , Bayer). e total iodine load (TIL) and IDR were calculated additionally.
Data Analysis.
All CT images were analyzed with multiplanar reconstructions and axial slices on dedicated software (Syngo.Via ™ , Siemens). e 17-segment model of the American Heart Association (AHA) was used to assess the segments of all coronary arteries [28] . All outcomes were recorded on a per-patient and on per-segment level. Assessment of coronary artery calcifications and stenosis was not within the scope of this article. However, Agatston score and calcium mass were collected from the radiology reports and evaluated between groups.
Image Analysis: Primary
Outcome. e primary outcome was defined as the proportion of scans with an intravascular attenuation between 325-500 HU. An intravascular attenuation of ≥325 HU was considered diagnostic [7, 29] . An intravascular attenuation >500 HU was considered unnecessarily high [13] . e intravascular attenuation was measured by one researcher, trained for objective assessment and blinded for treatment allocation (N. E.). Automatically drawn centerlines in all three coronary arteries were used. Circular regions of interest (ROIs) were manually drawn in the coronary arteries and epicardial fat to measure intravascular attenuation in HU and image noise (defined as the standard deviation of the intravascular attenuation). e epicardial fat measurements were used to calculate CNR and signal-to-noise ratio (SNR) (see secondary outcomes).
e overall mean (per-patient) intravascular attenuation was defined as the mean of the intravascular attenuation of all present segments. e circumference of the ROIs was kept as large as possible (minimal surface 1 mm 2 ) whilst avoiding arterial walls, intravascular plaques, and stents. In case of a CABG, all segments with an assessable lumen were used to draw ROIs.
Image Analysis: Secondary
Outcome. CNR was determined as intravascular attenuation minus epicardial fat attenuation, divided by the standard deviation of the epicardial fat attenuation. Intravascular attenuation divided by the standard deviation of the intravascular attenuation was used to determine SNR [18, 21, 30] .
Both per-patient and per-segment subjective image qualities were assessed by the same, blinded, researcher by using a 4-point Likert scale: Poor-major artifacts and/or low intravascular attenuation; Sufficient-minor artifacts and/or insufficient intravascular attenuation, however still diagnostic for coronary assessment; Good-minimal artifacts and sufficient intravascular attenuation; and Excellent-no artifacts and sufficient intravascular attenuation.
2.6. Statistical Analysis. IBM SPSS software (version 23.0, IBM SPSS statistics, Chicago IL, USA) software was used for statistical analysis. Continuous variables are expressed as mean ± standard deviation and categorical variables as absolute numbers and percentages (%). Both intention-to-treat (ITT) and per-protocol (PP) analyses were performed to assess the robustness of the results. e ITTanalysis included randomized patients for whom outcome data were available. e PP analysis included a subset of patients with strict adherence to the assigned CM injection protocol. A chisquare test (χ 2 ) was used to compare categorical variables between groups. e t-test for independent samples was used for pairwise comparisons of continuous variables between groups. All p values were 2-sided, and a p < 0.05 was considered statistically significant.
Results
Patient Characteristics.
A total of 330 patients were randomly assigned to one of the three experimental study arms between April 2017 and July 2018. ree patients were excluded after randomization; one patient was randomized twice due to randomization software problems, and two patients were excluded because scanning was discontinued after the calcium scoring.
us, a total of 327 patients remained for the ITT analysis. A total of 41 patients without strict adherence to the assigned CM injection protocol were excluded from the PP analysis (n � 286). ese patients (group BW n � 13; group LBW n � 17; and group CO n � 11) received a different protocol for various reasons, e.g., flow rate had to be adjusted because it was not applicable to the needle size.
Randomization placed 112 patients in group BW, 108 patients in group LBW, and 107 patients in group CO. e distribution of baseline characteristics was similar between groups ( Table 2) .
CM Dose.
All injection protocol parameters can be found in Table 3 . Mean main bolus volume was 47.5 ± 17.8 mL for group BW, 44.7 ± 13.9 mL for group LBW, and 42.7 ± 11.5 mL for group CO. e mean flow rate for groups BW, LBW, and CO was 5.1 ± 1.7 mL/s, 4.8 ± 1.2 mL/s, and 4.6 ± 1.0 mL/s, respectively. Although small differences existed in injection parameters between groups, a significant difference was found in all injection Table 4 . e proportion of patients with an optimal intravascular attenuation predefined as 325-500 HU was 83.9% in group BW, 84.3% in group LBW, and 86.9% in group CO. No significant differences in proportions were found between the groups (Figure 2 ). e difference in mean intravascular attenuation between groups BW and LBW was significant (p � 0.024), but not between the other pairwise comparisons ( Table 4 ). e mean intravascular attenuation was diagnostic (≥325 HU) in 95.5% of the individuals in the BW group, 89.8% in the LBW group, and 95.3% in the CO group ( Figure 3 and Table 4 ). No significant differences in these proportions were found between the groups. In one case in the LBW group, the intravascular attenuation was <325 HU due to an occlusion in the left subclavian vein. In the other cases, it was due to timing and/or movement artifacts.
Subjective Image Quality: Patient Level.
In group BW, the proportion of scans with good-excellent image quality was 94.6%; in the LBW group, this proportion was 86.1%; and in the CO group, it was 90.7%. Pairwise comparisons between all groups showed a significant difference between groups BW and LBW (p � 0.031) but not between the other groups ( Table 4 ). One scan in the BW group, scanned with a helical protocol, was graded nondiagnostic due to extensive motion artifacts (Figure 4) . Subjective image quality on a per-segment level can be found in Table 4 .
Per-Protocol Analysis.
e results of the PP analysis excluding 41 patients without strict adherence to the assigned CM injection protocol are presented in Appendix 2 and Appendix 3. ese results are similar to those from the ITT analysis. Table 2 . e complete dose report can be found in Table 5 .
Radiation Dose. All information on scan protocol and tube voltage selection is depicted in
Discussion
ree patient parameters (BW, LBW, and CO) were used to create tailored CM injection protocols in CCTA scanning. e use of different patient characteristics for tailoring CM injection protocols resulted in only minor differences in mean intravascular attenuation, with the highest attenuation found in the BW group. With regard to proportion of scans between 325-500 HU and proportion of diagnostic scans (mean overall intravascular attenuation ≥325 HU), no significant between-group differences were found. However, the higher mean intravascular attenuation value in group BW (compared to the LBW) did result in significantly higher proportions of scans with good to excellent image quality, which can be considered clinically relevant.
Previously, the CM injection protocol in our institution was based on BW categories (i.e., <50 kg, 50-69 kg, 70-90 kg, and >90 kg). is protocol resulted in a higher mean intravascular attenuation with a relatively wide standard deviation (464 ± 85 HU).
ere was a very wide range (186-672 HU) in intravascular attenuation values and an optimal intravascular attenuation between 325-500 HU was observed in 56.4% of patients. e CM injection protocols in the current study resulted in less variation in intravascular attenuation values between patients with standard deviation values around 60 HU and higher proportions of scans within the optimal window of 325-500 HU.
All CM injection parameters between groups BW and CO were significantly different. Group BW used a higher CM volume of 5 mL compared with group CO. is increase of 5 mL did not lead to a significant difference in intravascular attenuation nor to significantly more scans. Furthermore, the CM volume between groups LBW and BW did not differ significantly, although a significantly lower attenuation was found in group LBW. However, absence of a significant difference does not mean no difference is present [31] . It is possible that all small differences in patient parameters and injection protocol parameters resulted in the significant difference in attenuation. e current study shows that the total CM volume used does not have to be the deciding factor in selecting an individualized CM injection protocol. ese results also show that individualization to BW works equally well as more intricate patient parameters and formulas. e use of BW and LBW in personalization of CM injection protocols has been studied before in varying degrees. Liu et al. showed that BW-adapted injection protocols are feasible in high-pitch prospective CCTA [32] . Liu et al. did not adapt the scan protocol to the individual patient, and they only researched high-pitch CCTA scanning, whereas the current study used all currently available CCTA scan protocol techniques. Contrary to Liu et al., Tatsugami et al. did adapt their scan protocol to BMI and showed similar results to the current study [33] . In the current study, scan protocol adaptation was performed by automated tube voltage software (ATVS). is may be more specific compared to only using patients' BMI, as the addition of ATVS takes multiple other factors into account; not only body habitus but also scan protocol is taken into account. Furthermore, a study conducted by Bae et al. researched different patient parameters. ey stipulated that BW is the most important patient-related factor for intravascular attenuation [7] . Only one study investigated the use of LBW in CTA of the aorta [34] . is study did not find any significant differences in intravascular attenuation between LBW and BW, which is different from the findings in the current study. Lastly, to our knowledge, this is the first study to individualize the injection protocols to the patients' CO.
e current study has some limitations. Due to lack of correlation with invasive angiography, it could not be verified whether a higher proportion of patients with 6 Contrast Media & Molecular Imaging , and circumflex artery (Cx). Group CO resulted in an increased number of scans between 325 and 500HU. However, group BW had less scans <325 HU. All these differences were not significantly different. Of these three, group LBW had a lower attenuation and less scans >325 HU.
optimal intravascular attenuation (325-500 HU) resulted in a more accurate diagnosis and decreased underestimation of calcifications. Second, in the current study, CO was calculated with the help of a formula, and CO measurement was not performed.
To conclude, personalization of CM injection protocols to BW, LBW, and CO, and scan time and tube voltage in CCTA resulted in low variation in intravascular attenuation between patients in the three groups and a high proportion of scans with an optimal intravascular attenuation. e results suggest that personalized CM injection protocols based on LBW or CO have no additional benefit when compared to CM injection protocols based on BW.
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